Tipifarnib and naxitamab for neuroblastoma that has returned
Treatments studied
Part of Cancer clinical trials.
This study tests two drugs, tipifarnib and naxitamab, given together for children and young adults whose neuroblastoma has come back or did not go away with standard treatment. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 21 or younger when first diagnosed with neuroblastoma, and you are now older than 1 year.
- The neuroblastoma has come back after treatment (relapsed) or did not go away completely with standard treatment (refractory).
- You currently have signs of active neuroblastoma that can be measured on a scan or in a biopsy.
- You have recovered from the side effects of recent cancer treatments, and at least 2 weeks have passed since chemotherapy, 4 weeks since immunotherapy, and 30 days since radiation therapy.
- You are generally able to care for yourself (performance score of 50 or higher) and your organs (liver, kidneys, heart, blood counts) are working well enough.
- If you are of childbearing potential, you must have a negative pregnancy test and use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.